Redhill Biopharma Ltd
redhillbio.comWhat Do They Do?
Develops medicines for gut, infectious and cancer-related diseases and commercializes Talicia, a treatment for H. pylori infection in adults, through wholesale distributors and a U.S. partnership.
20-F for FY2025, filed Apr 27, 2026We are a specialty biopharmaceutical company, primarily focused on U.S. development and commercialization of drugs for GI diseases…View ↗
We are currently focused primarily on the advancement of our development pipeline of clinical-stage therapeutic candidates. We also…View ↗
Talicia® is our proprietary drug approved by the FDA for marketing in the U.S. for the treatment of H. pylori infection in adults. Talicia®…View ↗
The Company sold products mainly to wholesale distributors. Revenue was recognized at a point in time when control over the product was…View ↗
On October 25, 2025, we announced the signing of a strategic partnership with Cumberland, whereby Cumberland invested $4 million payable in…View ↗
Who Are Their Customers?
Product sales go mainly to wholesale distributors. Pharmaceutical partners commercialize licensed products in specific territories; in the U.S., Cumberland shares Talicia commercialization with Talicia Holdings.
20-F for FY2025, filed Apr 27, 2026The Company sold products mainly to wholesale distributors. Revenue was recognized at a point in time when control over the product was…View ↗
Our current pipeline consists of five therapeutic candidates, part of which are in mid-to-late stage clinical development. We generate our…View ↗
On October 25, 2025, we announced the signing of a strategic partnership with Cumberland, whereby Cumberland invested $4 million payable in…View ↗
Do Revenues Turn Into Profits?
No. It lost $429K in .
20-F for FY2025, filed Apr 27, 2026
20-F for FY2025, filed Apr 27, 2026
−$429KView ↗
How Are They Changing?
Disease focus
The company described its focus as gastrointestinal and infectious diseases in the older report; the latest report adds oncology to that stated focus.
20-F for FY2022, filed Apr 28, 2023 20-F for FY2025, filed Apr 27, 2026We are a specialty biopharmaceutical company, primarily focused on gastrointestinal (“GI”) and infectious diseases. Our primary goal is to…View ↗
We are a specialty biopharmaceutical company, primarily focused on U.S. development and commercialization of drugs for GI diseases…View ↗
Commercial portfolio
The older report described U.S. commercialization of Talicia and Aemcolo alongside pipeline development; the latest centers on pipeline advancement and identifies Talicia as its commercial product.
20-F for FY2022, filed Apr 28, 2023 20-F for FY2025, filed Apr 27, 2026We are currently focused primarily on the advancement of our development pipeline of clinical-stage therapeutic candidates. We also…View ↗
Who Do They Compete With?
Competes with Juvisé Pharmaceuticals, Phathom Pharmaceuticals, Endo International, and Novast Labs
20-F for FY2025, filed Apr 27, 2026Talicia® faces competition in the U.S. from certain branded prescription therapies indicated for the treatment of H. pylori infection…View ↗
Loading...
